New Delhi, Jan. 10 -- In the Climate Change series, we have covered international negotiations on climate change under the aegis of the United Nations Framework Convention on Climate Change (UNFCCC), ... Read More
India, Jan. 10 -- Pfizer Inc. (PFE) announced positive results from Cohort 3 of the pivotal BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI (flu... Read More
India, Jan. 10 -- As can happen in any derby in football, the Madrid derby between Atletico Madrid and Real Madrid in the semifinal stage of the Supercopa de Espana in Jeddah saw tempers boil over. Tw... Read More
India, Jan. 10 -- To say that Shubhankar Sharma had a bad 2025 will be putting it mildly. The 29-year-old, India's permanent fixture on the DP World Tour for close to a decade, competed in 28 European... Read More
New Delhi, Jan. 10 -- India loves cars. We love to buy them, polish them, name them, post delivery selfies online and occasionally fantasize about driving like the wind. Then, reality strikes. The mom... Read More
India, Jan. 10 -- As of December 2025, 51.82% is owned by Foreign Promoters and 48.18% by Public. Institutional holds 20.81% (Insurance Companies 3.15%) and Non-Institutional holds 27.37% as Public s... Read More
India, Jan. 10 -- As of December 2025, 26.38% is owned by Indian Promoters and 73.62% by Public. Top four Promoters holding highest number of shares of Beryl Drugs Ltd. company are Sanjay Sethi (5.52... Read More
India, Jan. 10 -- The Elite National Boxing Championships here draws to a close but there was no end to the misery of the boxers. On a freezing winter night, several teams reported that they have been... Read More
Vadodara, Jan. 10 -- Ahead of the first ODI against New Zealand on Sunday, Indian batting legend Virat Kohli is just 25 runs away from becoming the third player to score 28,000 international runs afte... Read More
India, Jan. 10 -- Johnson & Johnson (JNJ) announced new longer-term follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating RYBREVANT (amivantamab-vmjw), a bispecific antibody... Read More